Top Markets
#1 Helium Helium +110.72%
#2 MowCat MowCat +83.79%
#3 Seeker Seeker +72.11%
#4 AI XOVIA AI XOVIA +52.42%
#5 UnifAI Network UnifAI Network +33.65%
#6 Pons Pons +30.52%
#7 Tensor Tensor +26.60%
#8 TENDIES TENDIES +25.33%
#9 pipedog pipedog +22.04%
#10 Zylo Ecosystem Zylo Ecosystem +21.96%
Coin of the day
Helium Helium
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT
Clasificación en acciones #11443
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Precio por acción
$8.74
Última sincronización: 2026-08-28
Capitalización bursátil
$699.74M
Cambio (1 día)
-4.85%
Cambio (1 año)
-2.29%
País
US
Comercio BridgeBio Oncology Therapeutics Inc. (BBOT)

Categoría

Healthcare
Ratio P/S de BridgeBio Oncology Therapeutics Inc. (BBOT)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de BridgeBio Oncology Therapeutics Inc., el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de BridgeBio Oncology Therapeutics Inc. desde 2026 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
Not enough data for the provided dates.
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH